Characterising the Economic Burden of Functional Dyspepsia: A Cost-of-Illness Study of Direct and Indirect Costs.
United European Gastroenterol JSep 1, 2026
Daan H C A Bosch, Brigitte A B Essers, Abraham B Beckers et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial assessed the economic burden of functional dyspepsia (FD) in 73 patients, focusing on direct and indirect costs. The mean annual total costs were €12,192, with €10,240 attributed to indirect costs. A significant finding was that higher disease-specific quality of life (QoL) correlated with lower costs, with a regression slope of -€4726 per 0.1-point increase in QoL.
Key findings
- Mean annual total costs for FD patients were €12,192.
- Indirect costs accounted for €10,240 of the total costs.
- Higher disease-specific QoL was associated with lower annual costs (slope = -€4726 per 0.1-point increase in QoL).
- Symptom severity and mental health scores did not significantly correlate with costs.
Why it matters
Understanding the economic burden of functional dyspepsia can help clinicians identify patients at risk for higher costs, enabling more effective management strategies and resource allocation.